Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase

Transplantation Proceedings

Volumn 42, Issue 8, 2010, Pages 2994-2996

  Marzoa Rivas, R ^a   Paniagua Martin M J ^a   Barge Caballero, E ^a   Pedrosa Del Moral, V ^a   Barge Caballero, G ^a   Grille Cancela, Z ^a   Naya Leira, C ^a   Farinas Garrido P ^a   Blanco Canosa, P ^a   Mosquera, V ^a   Castro Beiras, A ^a   Crespo Leiro, M G ^a  

^a Hospital Universitario A Corua   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TACROLIMUS;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT INFECTION; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DELAYED-ACTION PREPARATIONS; ECHOCARDIOGRAPHY; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TACROLIMUS;

EID: 77958613209     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.08.020     Document Type: Article

References (10)

1. B.W. Pinsky, S.K. Takemoto, and K.L. Lentine Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression Am J Transplant 9 2009 2597
2. J.G. O'Grady, A. Asderakis, and R. Bradley Multidisciplinary insights into optimizing adherence after solid organ transplantation Transplantation 89 2010 627
3. Department of Health and Ageing Australian Therapeutic Goods Administration: Australian public assessment report for tacrolimus www.tga.gov.au/pmeds/auspar/auspar-prograf-xl.pdf May 2010 Accessed June 11, 2010
4. E. Galléego-Valcarce, A. Ortega-Cerrato, and F. Llamas-Fuentes Conversion to tacrolimus extendedrelease formulation: short-term clinical results Transplant Proc 41 2009 2326
5. B. Diez Ojea, M. Alonso Alvarez, and S. Aguado Fernandez Three-month experience with tacrolimus once-daily regimen in stable renal allografts Transplant Proc 41 2009 2323
6. M.R. First First clinical experience with the new once-daily formulation of tacrolimus Ther Drug Monit 30 2008 159
7. L.M. Marin-Gomez, M.A. Gomez-Bravo, and J.A. Alamo-Martinez Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study Transplant Proc 41 2009 2184
8. Z. Wlodarczyk, J.P. Squifflet, and M. Ostrowski Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial Am J Transplant 9 2009 2505
9. M. Crespo, M. Mir, and M. Marin De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels Transplant Proc 41 2009 2115
10. D. Anglicheau, C. Legendre, and P. Beaune Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update Pharmacogenomics 8 2007 835